Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6886 to 6900 of 7691 results

  1. Carotuximab with pazopanib for treating advanced angiosarcoma [ID1503]

    Discontinued [GID-TA10401]

    Technology appraisal guidance
    Discontinued

  2. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued [GID-TA10627]

    Technology appraisal guidance
    Discontinued

  3. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued [GID-TA11173]

    Technology appraisal guidance
    Discontinued

  4. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued [GID-TA10354]

    Technology appraisal guidance
    Discontinued

  5. Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

    Discontinued [GID-TA10480]

    Technology appraisal guidance
    Discontinued

  6. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued [GID-TA10284]

    Technology appraisal guidance
    Discontinued

  7. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued [GID-TA10166]

    Technology appraisal guidance
    Discontinued

  8. Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]

    Discontinued [GID-TA10203]

    Technology appraisal guidance
    Discontinued

  9. NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655]

    Discontinued [GID-TA10183]

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer [ID1168]

    Discontinued [GID-TA10208]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued [GID-TA10330]

    Technology appraisal guidance
    Discontinued

  12. Pancreatic cancer - capecitabine [ID389]

    Discontinued [GID-TAG394]

    Technology appraisal guidance
    Discontinued

  13. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued [GID-TA10325]

    Technology appraisal guidance
    Discontinued

  14. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued [GID-TA11238]

    Technology appraisal guidance
    Discontinued

  15. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued [GID-TA11239]

    Technology appraisal guidance
    Discontinued